2I
2I3.F Champions Oncology Inc
- Market cap
- EUR 58.2M
- P/E
- -
- P/B
- 16.85x
- ROE
- -43.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jul 2026.
Is 2I3.F undervalued?
Graham numberThe Graham number of Champions Oncology Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Champions Oncology Inc fundamental analysis
No fundamental analysis for Champions Oncology Inc yet.
Champions Oncology Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Champions Oncology Inc
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceut…
Full company profileChampions Oncology Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jul 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Champions Oncology Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 15.4M | 20.2M | 27.1M | 32.1M | 41.0M | 49.1M | 53.9M | 50.2M | 56.9M | 59.4M | 60.9M |
| Gross Profit | 5.71M | 9.69M | 12.8M | 15.2M | 19.6M | 25.5M | 24.3M | 20.8M | 28.6M | 28.5M | 30.8M |
| Operating Income | -6.81M | -1.35M | 270K | -1.47M | 338K | 607K | -4.45M | -6.92M | 4.85M | -1.03M | -1.64M |
| EBITDA | -6.64M | -994K | 876K | -643K | 1.52M | 2.23M | -2.20M | -5.05M | 6.49M | 348K | -380K |
| Net Income | -6.88M | -1.48M | 128K | -1.98M | 334K | 548K | -5.34M | -7.28M | 4.70M | -1.18M | -1.70M |
| EPS | -0.63 | -0.13 | 0.01 | -0.16 | 0.02 | 0.04 | -0.39 | -0.54 | 0.34 | -0.08 | -0.12 |
| Balance Sheet | |||||||||||
| Total Assets | 8.01M | 8.08M | 11.3M | 20.8M | 27.6M | 35.4M | 34.3M | 26.1M | 32.3M | 27.0M | 33.3M |
| Total Liabilities | 7.61M | 8.08M | 9.03M | 15.4M | 20.2M | 26.3M | 29.7M | 28.0M | 28.6M | 22.9M | 28.8M |
| Shareholders' Equity | 400K | 3.00K | 2.24M | 5.32M | 7.43M | 9.10M | 4.64M | -1.90M | 3.77M | 3.94M | 3.89M |
| Cash & Short-term Investments | 3.30M | 856K | 3.24M | 8.34M | 4.69M | 9.01M | 10.1M | 2.62M | 9.79M | 4.87M | 4.36M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.84M | -1.23M | 1.86M | 2.91M | -1.68M | 6.50M | 3.97M | -6.14M | 7.39M | -4.47M | -1.97M |
| Capital Expenditure | 766K | 1.23M | 834K | 2.22M | 3.28M | 2.38M | 2.87M | 836K | 389K | 564K | 220K |
| Free Cash Flow | -3.61M | -2.46M | 1.03M | 685K | -4.96M | 4.11M | 1.08M | -6.97M | 7.00M | -5.04M | -2.19M |
| Ratios | |||||||||||
| ROE | -1,721.0% | -49,200.0% | 5.7% | -37.1% | 4.5% | 6.0% | -115.1% | - | 124.6% | -29.8% | -43.8% |
| ROA | -85.9% | -18.3% | 1.1% | -9.5% | 1.2% | 1.5% | -15.5% | -27.8% | 14.5% | -4.4% | -5.1% |
| Net Profit Margin | -44.7% | -7.3% | 0.5% | -6.1% | 0.8% | 1.1% | -9.9% | -14.5% | 8.3% | -2.0% | -2.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Champions Oncology Inc dividends
Champions Oncology Inc has not paid dividends in the last 9 fiscal years.
Who owns Champions Oncology Inc
- Insiders 26.83%
- Institutions 48.60%
- Public & others 24.57%
- Shares outstanding 13.9M
- Free float 6.04M
Champions Oncology Inc company profile
- Company name
- Champions Oncology Inc
- Ticker
- 2I3.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 214
- Fiscal year end
- April
- Address
- One University Plaza, Hackensack, NJ, United States, 07601
- Phone
- 201 808 8400
- Website
- championsoncology.com
About Champions Oncology Inc
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Champions Oncology Inc management
5- Dr. Ronnie Morris M.D.Executive Chair · born 1966
- Mr. Robert BraininCEO & Director · born 1971
- Mr. David Barry Miller M.B.A.Chief Financial Officer · born 1969
- Dr. Maria Mancini Ph.D.Chief Operating Officer
- Dr. Marianna Zipeto Ph.D.Executive Vice President of Growth, Strategy & Enablement